Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.36 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649444 | 1.00 | GAA (0.47) | GAARAB9AITGB1ITGA4ITGB2 | |
| SCHEMBL4648600 | 0.93 | ITGB1 (0.52) | GAARAB9AITGB1ITGA4ITGB2 | |
| SCHEMBL4649378 | 0.93 | ITGB1 (0.52) | GAARAB9AITGB1ITGA4ITGB2 | |
| SCHEMBL4648805 | 0.91 | ITGB1 (0.49) | GAARAB9AITGB1ITGA4ITGB2 | |
| SCHEMBL4648806 | 0.91 | ITGB1 (0.49) | GAARAB9AITGB1ITGA4ITGB2 | |
| Tetrahydrofuran SCHEMBL4648660 | 0.88 | ITGB1 (0.47) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL5706239 | 0.87 | GAA (0.45) | GAARAB9AITGB1ITGA4ITGB2 | |
| SCHEMBL4649064 | 0.86 | ITGA4 (0.59) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL4649073 | 0.86 | ITGA4 (0.59) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL4648129 | 0.84 | ITGA4 (0.53) | ITGB1ITGA4ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701933-B1 | NOVEL COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-20070043113-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1701933-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005061440-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043113-A1 | Novel compounds | VCAM1, ICAM1, EPCAM | GAA 279/4885RAB9A 1012/4885ITGB1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.